News (22)

Vaccine-induced prothrombotic immune thrombocytopenia: pathogenetic and epidemiological issues of concern AQ
Transcript : Innate Pharma S.A., H1 2020 Earnings Call, Sep 08, 2020
Tikehau Capital : Universal Registration Document and half year financial report as at 30 June 2019 PU
Tikehau Capital : Assets under management of €23.4 billion at 30 June 2019, up 6% over the first-half and 16% over the last 12 months PU
Tikehau Capital: Assets under management of €23.4 billion at 30 June 2019, up 6% over the first-half and 16% over the last 12 months BU
Tikehau Capital : Appoints Laure Perréard as Chief Financial Officer BU
Tikehau Capital Announces Executive Changes CI
BPCE : pierre Valentin elected Chairman of the Supervisory Board of Groupe BPCE GL
Banque de France : Working Papers n° 533 - Capital Regulation in a Macroeconomic Model with Three Layers of Default. PU
Banque de France : Working Papers n° 530 - Land Collateral and Labor Market Dynamics in France PU
Banque de France : Working Papers n° 528 - Assessing the macroeconomic effects of LTROS PU
Banque de France : Working Papers n° 526 - Trade networks and colonial trade spillovers PU
Banque de France : Working Papers n° 525 - How Fiscal Policy Affects the Price Level: Britain’s First Experience with Paper Money PU
Banque de France : Working Papers n° 523 - How do oil price forecast errors impact inflation forecast errors? An empirical analysis from French and US inflation forecasts PU
Banque de France : Working Papers n° 522 - Euro Area business cycles in turbulent times: convergence or decoupling? PU
Banque de France : Working Papers n° 520 - Variable Selection in Predictive MIDAS Models PU
Banque de France : Working Papers n° 519 - Pre-crisis credit standards: monetary policy or the savings glut? PU
Banque de France : Working Papers n° 518 - Options Embedded in ECB Targeted Refinancing Operations PU
Banque de France : Working Papers n° 514 - Product and Labor Market Regulations, Production Prices, Wages and Productivity (copie 1) PU
Banque de France : Working Papers n° 512 - Euro Area monetary policy shocks: impact on financial asset prices during the crisis? PU
Banque de France : Working Papers n° 511 - Economic Policy Uncertainty and Inflation Expectations PU
Fairway Project Operations Update PU

Companies (13)

VERU INC. 148 M $
Logo Veru Inc.

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the manag ...

ARD GRUP BILISIM TEKNOLOJILERI ANONIM SIRKETI 190 M $
Logo Ard Grup Bilisim Teknolojileri Anonim Sirketi

Ard Grup Bilisim Teknolojileri AS is a Turkey-based information technology (IT) company. It focuses on architecture implementation, software development, and cyber security providing customizable products and services. Its offering includes a wide range o ...

MEDICINOVA, INC. 67 M $
Logo MediciNova, Inc.

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activiti ...

TALPHERA, INC. 18 M $
Logo Talphera, Inc.

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidate ...

PARADIGM BIOPHARMACEUTICALS LIMITED 58 M $
Logo Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) ...

BIOCARDIA, INC. 127 M $
Logo BioCardia, Inc.

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous monon ...

AVALO THERAPEUTICS, INC. 12 M $
Logo Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-0 ...

EDESA BIOTECH, INC. 14 M $
Logo Edesa Biotech, Inc.

Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for ...

ARGENT BIOPHARMA LIMITED 11 M $
Logo Argent BioPharma Limited

Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologi ...

MESOBLAST LIMITED 841 M $
Logo Mesoblast Limited

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product pl ...

PEAK BIO, INC. 198 874 $
Logo Peak Bio, Inc.

Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Company’ ...

INCANNEX HEALTHCARE INC. 45 M $
Logo Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain ...

ADVANCED LIFE SCIENCES HOLDINGS, INC. 107 880 $
Logo Advanced Life Sciences Holdings, Inc.

Advanced Life Sciences Holdings, Inc. is a United States-based biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, cancer, and respiratory diseases. The Com ...


12Next

Insiders

Picture Laure Duhot
Laure Duhot

Laure Duhot currently holds several positions as an Independent Non-Executive Director at Safestore Holdings Plc, NB Global Monthly Income Fund Ltd., Primary Health Properties Plc, and Non-Executive Director at Safestore Ltd.
She is also a Director at Lifestory Group Ltd.
and a Managing Director at Duhot-Consult Ltd.
In the past, she held positions as Managing Director at Grainger Plc from 2012 to 2016, Independent Non-Executive Director at MXF Fund Ltd., Independent Non-Executive Director at Inland Homes PLC from 2018 to 2020, Independent Director at Orpea SA from 2022 to 2023, and Non-Executive Director at Thames Valley Housing Association Ltd.
She also worked as Head-Investment & Capital Markets-Europe at Lendlease Group.


Picture Laure Perréard
Laure Perréard

Currently, Laure Perréard holds the position of Chief Financial Officer of Tikehau Capital SCA.


Picture Laure Frères
Laure Frères

Ms. Laure Frères is an Executive Vice President, Head-Quality & Medical at Orpea SA.


Picture Laure Thibierge
Laure Thibierge

Laure Thibierge is currently working as a Senior Investment Manager at MBO+ SAS since 2014.
Prior to this, Laure worked as a Director at CFDP Assurances SA.





Picture Laure Girodet
Laure Girodet

Laure Girodet is currently a Director at Veolia WTS USA, Inc. She was previously a Director-Support Functions at Lydec SA and a Director at Vigie SA. She obtained an undergraduate degree from Ecole Nationale des Ponts et Chaussées.


Picture Laure Safran
Laure Safran

Laure Safran worked as a Partner at Fraser Milner Casgrain LLP from 2004 to 2012.





Picture Laure Reinhart
Laure Reinhart

Laure Reinhart is currently the Director at the Institut des Hautes Etudes pour la Science et la Technologie, the Director at the Institut National de Recherche en Informatique et Automatique, the Director at L'Agence Nationale de la Recherche, the Director at the Institut National de la Propriété Industrielle, the President of Scientipole Initiative Services SASU, the President of Île de Science, and the President of Scientipole Growth.
Dr. Reinhart previously worked as the Director at Safran SA and as the Deputy Managing Director at the Agence Nationale de Valorisation de la Recherche from 2008 to 2014.
Dr. Reinhart received undergraduate and doctorate degrees from Université Pierre et Marie Curie.


Picture Laure Muller
Laure Muller

Laure Muller is currently working as the Director-Project Management at Relevant Ads, Inc. since 2010.
Ms. Muller has a graduate degree from the Université des Sciences et Technologies de Lille and an undergraduate degree from the University of Strasbourg.




Picture Laure Brasch
Laure Brasch

At Franklin Park, Laure leads the firm’s regulatory compliance functions.
Laure is also involved in the post-investment monitoring efforts, which include fund manager oversight, investment compliance and performance reporting, and the firm’s operational due diligence efforts, providing pre-investment assessments of the back office infrastructure of prospective fund managers, and she interacts with clients on a variety of portfolio matters.
Prior to joining Franklin Park in 2006, Laure worked with SEI Investments and Kreischer, Miller & Co., a public accounting firm.
She is a Certified Public Accountant.
Laure received a B.B.A.
in Accounting from Temple University.



Picture Laure Fauchet
Laure Fauchet

Laure Fauchet worked as a Strategist at Société Générale SA (UK) and as a Junior Strategist at SG Securities (Paris) SAS.







Picture Laure Thomas
Laure Thomas

Laure Thomas worked as a Director at SEB SA from 2013 to 2017.
She also served as a Member-Supervisory Board at Venelle Investissement.
Ms. Thomas obtained an undergraduate degree from Ecole Superieure de Commerce de Dijon.


Picture Werner Laure
Werner Laure

Werner Laure has worked as the Head of Human Resource Management at BKS Bank AG since 1989.













Picture Laure Lesme-Berthomieux
Laure Lesme-Berthomieux

Laure Lesme-Berthomieux currently works at Caisse Régionale de Crédit Agricole Mutuel du Nord Est SCI, as Managing Director, Predica Prévoyance Dialogue du Crédit Agricole SA, as Director from 2020, and Crédit Agricole Assurances SA, as Director.





Picture Laure Bros
Laure Bros

Laure Bros is the founder of Ennov SAS, which was founded in 1999.
At Ennov SAS, Bros holds the title of Vice President-Sales & Marketing starting in 1999.












Picture Laure Dozon
Laure Dozon

Laure Dozon served as a Director at CRCAM de Touraine Poitou from 2010 to 2011.


Picture Laure Chouchan
Laure Chouchan

Laure Chouchan is a professional with experience in various firms.
Currently, she is a Member-Supervisory Board at Hopscotch Groupe SA since 2004.
Previously, she worked as a Director-Games at FremantleMedia France SAS from 2007 to 2016 and as a Member-Supervisory Board at Le Public Système SA from 2004 to 2010.
Ms. Chouchan is a graduate from Université Paris Dauphine-PSL.




Picture Laure Garrido
Laure Garrido

Laure Garrido has a current job as a Director at Société de Construction et de Reparation de Materiel Aeronau.








Picture Laure Baert
Laure Baert

Laure Baert is an Independent Director at Deceuninck NV since 2022.
She graduated from Solvay Business School of Economics & Management in 2015.


Picture Laure Lita
Laure Lita

Laure Lita is currently the Director at Centre Vincent van Gogh-Chab ASBL since 2020.





Picture Laure Némée
Laure Némée

Laure Némée worked as a Software Engineer at NPTV SA from 2001 to 2007 and as a Principal at ScrOOn SA from 2008 to 2009.
She obtained an undergraduate degree from École supérieure d'électricité in 2001.




Picture Laure Thibaud
Laure Thibaud

Laure Thibaud worked as SVP-Corporate Communications at Sanofi and as EVP-Communications & Sustainable Development at AXA Group Solutions.



Picture Laure Chatin
Laure Chatin

Laure Chatin has a current job as the Managing Director at IMA France.



Picture Laure Goupil
Laure Goupil

Laure Goupil currently works at AXA Venture Partners SAS, as Head of Investor relations from 2020.
Ms. Goupil received her graduate degree in 2014 from Institut Supérieur du Commerce.



Picture Laure Lefevre
Laure Lefevre

Laure Lefevre is currently a Director at Pharcor SAS.


Picture Laure Tallon
Laure Tallon

Laure Tallon graduated from École des Hautes Études Commerciales de Paris in 2019.



Picture Laure Pourageaud
Laure Pourageaud

Laure Pourageaud is currently the Chief Human Resources Officer at Sodexo Benefits & Rewards Services and Pluxee NV.
She previously worked as the Chief People Officer-Europe at Sage SA and the Chief People Officer at TalentSoft SA. She received an undergraduate degree from Université Paris 1 Panthéon-Sorbonne and a graduate degree from Sorbonne Université.



Picture Laure Desbrosses
Laure Desbrosses

Laure Desbrosses is a Senior Credit analyst at LBP AM since 2022.
Prior to this, she worked as a Senior Credit Analyst at Allianz Global Investors GmbH (France) from 2013 to 2021.
Before that, she was a Research Analyst at Oddo BHF SCA (Broker) from 2011 to 2012.
Additionally, she worked as a Vice President at CBAM SAS in 2022.








Picture Laure E. Park
Laure E. Park

Laure E.
Park
is currently a member of the Healthcare Businesswomens Association and the Senior VP-Investor Relations & Corporate Affairs at Endo International Plc.
Previously, she worked at Quest Diagnostics, Inc. for 23 years as the Vice President-Communications & Investor Relations.
She also worked as a Manager at Deloitte & Touche LLP.
Ms. Park received her undergraduate degree from the University of North Dakota in 1987.


Picture Laure L. Wang
Laure L. Wang

Laure L.
Wang
is a co-Founder and Managing Director of Asia Alternatives.
Ms. Wang co-leads Asia Alternatives' Hong Kong office, which serves as the Firm's base for fund and direct investing, market research, and portfolio management.
Ms. Wang is on the Firm's Investment Committee.
Prior to launching Asia Alternatives, Ms. Wang had over twelve years of private equity experience and has lived and worked in Asia for over eight years.
Ms. Wang was a General Partner of Pacific Venture Partners ("PVP"), a pan-Asian venture capital firm with over US$800 million under management, and was one of five members on its investment committee.
At PVP, she co-headed the China and US operations, leading and managing investments in the technology industry.
Prior to her involvement with PVP, Ms. Wang was a Vice President at Goldman, Sachs & Co. ("Goldman Sachs") in the Principal Investment Area of the Merchant Banking Division.
Over an eight year period at Goldman Sachs, Ms. Wang was a key member of the Principal Investment Area in the Hong Kong office and the Menlo Park office, investing over US$400 million in 19 transactions across Asia and the US.
In addition, Ms. Wang served as the Chief Operations Officer for the Menlo Park investing team and co-headed the workout of a US$1.6 billion global distressed portfolio.
Previously, Ms. Wang also worked for Warburg Pincus in Hong Kong.
Ms. Wang received an M.B.A.
from Harvard Business School and holds a bachelors degree in Economics and International Relations with honors from Stanford University.
She is fluent in Mandarin Chinese and has working knowledge of Japanese and French.


Picture Daniel Laure
Daniel Laure

Daniel Laure currently works at Total New Energies USA, Inc., as President & Chief Executive Officer from 2016.
Mr. Laure also formerly worked at SunPower Corp., as Director from 2016 to 2017, Teréga SAS, as Director, Total Solar INTL SAS, as VP-Strategy, Markets & Information Technology, and Total Gas & Power USA Biotech, Inc., as VP-Strategy, Markets & Information Technology.
Mr. Laure received his undergraduate degree from Ecole Nationale des Ponts et Chaussées and graduate degree from Université Paris II Panthéon Assas.



Picture Laure Baume
Laure Baume

Laure Baume currently works at MHD Moët Hennessy Diageo SAS, as Chairman & Chief Executive Officer from 2021.
Ms. Baume also formerly worked at Aéroports de Paris ADP, as Deputy Chief Executive Officer from 2014 to 2018, Orpea SA, as Independent Director, Média Aéroports de Paris SAS, as Director, Epigo SAS, as Director, Club Med SAS, as Vice President-Worldwide Strategic Marketing, Kraft Foods International, Inc., as Manager-Innovation Product, Mondelez France SAS, as Assistant Product Manager-Milka Brand, Société de Distribution Aéroportuaire SAS, as Member-Management Board, and Relay@ADP SAS, as Member-Management Board.
Ms. Baume received her undergraduate degree from École des Hautes Études Commerciales de Paris and undergraduate degree from the University of Liege.







Picture Laure Grimonpret-Tahon
Laure Grimonpret-Tahon

Laure Grimonpret-Tahon currently works at Compagnie Générale Immobilière SA, as Legal Director & Head-Internal Affairs from 2014, Cgi Luxembourg SA, as Legal Director & Head-Internal Affairs from 2014, and Rubis SCA, as Independent Member-Supervisory Board from 2015.
Ms. Grimonpret-Tahon also formerly worked at Conseillers & Gestion & Informatique SAS, as Legal Director & Head-Internal Affairs and Umanis SA, as Member.
Ms. Grimonpret-Tahon received her graduate degree from ESSEC Business School.

No results for this search